Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse model

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 4, 2008, Pages 314-323

  Ulu, Arzu ^a   Davis, Benjamin B ^b   Tsai, Hsing Ju ^a   Kim, In Hae ^a   Morisseau, Christophe ^a,c   Inceoglu, Bora ^a   Fiehn, Oliver ^d   Hammock, Bruce D ^a,c   Weiss, Robert H ^e,f,g  

^a Department of Entomology ^*  (United States)

^b Center for Health and the Environment   (United States)

^c Cancer Research Center   (United States)

^d Department of Internal Medicine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Affairs Medical Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1 adamantan 3 (5 (2 (2 ethylethoxy)ethoxy)pentyl) urea; Apo E knockout mice; Atherosclerosis; Epoxyeicosatrienoic acid; Soluble epoxide hydrolase

Indexed keywords

1 ADAMANTAN 3 [5 [2 (2 ETHYLETHOXY)ETHOXY]PENTYL]UREA; ANGIOTENSIN II; APOLIPOPROTEIN E; ARACHIDONIC ACID; CHOLESTEROL; CYTOCHROME P450; DIHYDROXYICOSATRIENOIC ACID; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; ICOSANOID; LINOLEIC ACID; OXYLIPIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DESCENDING AORTA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INHIBITION; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ATHEROSCLEROSIS; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; MOLECULAR WEIGHT; MOUSE MUTANT; PATHOLOGY; PILOT STUDY; SOLUBILITY;

ANGIOTENSIN II; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; EPOXIDE HYDROLASES; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PILOT PROJECTS; SOLUBILITY;

EID: 58149350130     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318185fa3c     Document Type: Article

References (36)

1. Vinereanu D. Risk factors for atherosclerotic disease: present and future. Herz. 2006;31(Suppl 3):5-24.
2. Go AS, Chertow GM, Fan D, McCulloch CE, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
3. Roberts MA, Hare DL, Ratnaike S, et al. Cardiovascular biomarkers in ckd: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis. 2006;48:341-360.
4. Bertolotti M, Maurantonio M, Gabbi C, et al. Hyperlipidaemia and cardiovascular risk. Aliment Pharmacol Ther. 2005;22(Suppl 2): 28-30.
5. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54: 24-38.
6. Chiamvimonvat N, Ho CM, Tsai HJ, et al. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol. 2007;50:225-237.
7. Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005;46:975-981.
8. Schmelzer KR, Kubala L, Newman JW, et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A. 2005;102:9772-9777.
9. Jung O, Brandes RP, Kim IH, et al. Soluble epoxide hydrolase is a main effector of angiotensin ii-induced hypertension. Hypertension. 2005;45: 759-765.
10. Imig JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690-694.
11. Schmelzer KR, Inceoglu B, Kubala L, et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A. 2006;103:13646-13651.
12. Yu Z, Davis BB, Morisseau C, et al. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol. 2004;286:F720-F726.
13. Libby P. Atherosclerosis: the new view. Sci Am. 2002;286:46-55.
14. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci. 1999;892:108-118.
15. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in Apoe-deficient mice. Circulation. 2001;103:448-454.
16. Kim IH, Tsai HJ, Nishi K, et al. 1,3-Disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem. 2007;50: 5217-5226.
17. Olearczyk JJ, Field MB, Kim IH, et al. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther. 2006;318:1307-1314.
18. Rodal SK, Skretting G, Garred O, et al. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell. 1999;10:961-974.
19. Gabriel KI, Cunningham CL. Effects of topiramate on ethanol and saccharin consumption and preferences in C57bl/6j mice. Alcohol Clin Exp Res. 2005;29:75-80.
20. Blair-West JR, Denton DA, McBurnie MI, et al. The effect of adrenocorticotrophic hormone on water intake in mice. Physiol Behav. 1996;60:1053-1056.
21. Jones PD, Wolf NM, Morisseau C, et al. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem. 2005;343:66-75.
22. Huster D, Purnat TD, Burkhead JL, et al. High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J Biol Chem. 2007;282:8343-8355.
23. Paigen B, Morrow A, Holmes PA, et al. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240.
24. Jones PD, Tsai HJ, Do ZN, et al. Synthesis and sar of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006;16:5212-5216.
25. Fang X, Kaduce TL, Weintraub NL, et al. Pathways of epoxyeicosa-trienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem. 2001;276: 14867-14874.
26. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome p450 epoxygenase-derived eicosanoids. Science. 1999;285: 1276-1279.
27. Moghaddam MF, Grant DF, Cheek JM, et al. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med. 1997;3:562-566.
28. Ishizaki T, Takahashi H, Ozawa T, et al. Leukotoxin, 9,10-epoxy-12- octadecenoate causes pulmonary vasodilation in rats. Am J Physiol. 1995; 268:L123-L128.
29. Ozawa T, Sugiyama S, Hayakawa M, et al. Existence of leukotoxin 9,10-epoxy-12-octadecenoate in lung lavages from rats breathing pure oxygen and from patients with the adult respiratory distress syndrome. Am Rev Respir Dis. 1988;137:535-540.
30. Kosaka K, Suzuki K, Hayakawa M, et al. Leukotoxin, a linoleate epoxide: its implication in the late death of patients with extensive burns. Mol Cell Biochem. 1994;139:141-148.
31. Moran JH, Mitchell LA, Bradbury JA, et al. Analysis of the cytotoxic properties of linoleic acid metabolites produced by renal and hepatic p450s. Toxicol Appl Pharmacol. 2000;168:268-279.
32. Fukushima A, Hayakawa M, Sugiyama S, et al. Cardiovascular effects of leukotoxin (9, 10-epoxy-12-octadecenoate) and free fatty acids in dogs. Cardiovasc Res. 1988;22:213-218.
33. Thompson DA, Hammock BD. Dihydroxyoctadecamonoenoate esters inhibit the neutrophil respiratory burst. J Biosci. 2007;32:279-291.
34. Newman JW, Morisseau C, Harris TR, et al. The soluble epoxide hydrolase encoded by Epxh2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A. 2003;100: 1558-1563.
35. Enayetallah AE, Grant DF. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem Biophys Res Commun. 2006;341:254-260.
36. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A. 2006;103: 18733-18738.